Mexico has one of the highest rates of type 2 diabetes in the world with nearly 12% of the adult population diagnosed. The disease results in 70,000 deaths per year making diabetes the leading cause of death for the country. The prevalence of diabetes is projected to continue to increase in the coming years.

Scienta Farma, S.A. de C.V. distributes DPNCheck for NeuroMetrix in Mexico. The largest market opportunity for DPNCheck is within the six public institutions that provide healthcare services to the majority of Mexico’s 120 million citizens. Scienta Farma focuses their marketing and sales efforts on gaining government contracts with these institutions.

"Mexico is a very important component of our international strategy for DPNCheck and we believe this initial sale will help accelerate Scienta Farma’s efforts to expand DPNCheck adoption within the other major government healthcare institutions," said Michael MacDonald, NeuroMetrix SVP of Commercial Operations.

"DPNCheck is a significant clinical advance for the care of diabetic patients in Mexico," said Alberto Elias Fernandez, Executive Vice President of Scienta Farma. "We are excited to be partnering with NeuroMetrix to bring this important technology to clinicians in Mexico."

DPNCheck is a quantitative nerve conduction test that is used by physicians and health care professionals to evaluate systemic neuropathies such as diabetic peripheral neuropathy, or DPN.

It is designed to be used at the point-of-care to objectively detect, stage, and monitor DPN. The device measures nerve conduction velocity and response amplitude of the sural nerve, a nerve in the lower leg and ankle. These parameters are recognized as sensitive and specific biomarkers of DPN.

NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders.